multi target TKI

Apitolisib - Axitinib - Cabozantinib - Dovitinib - Pazopanib - Sorafenib - Sunitinib - Tivozanib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

advanced breast cancer (metastatic)

lapatinib
Johnston (EGF30008) , 2009      NCTlapatinib + letrozoleletrozole alone HR positive Low risk of bias conclusive -29%-22%
Di Leo, 2008        NCTlapatinib + paclitaxelpaclitaxel alone 1st line Low risk of bias negative -10%-14%
sorafenib
Baselga, 2012     sorafenib + capecitabinecapecitabine alone HER-2 negative Low risk of bias suggesting-42%-14%
Schwartzberg, 2013      NCTsorafenib + gemcitabine or capecitabinegemcitabine or capecitabine alone 2nd line HER-2 negative Exploratory suggesting-36%1%
Gradishar, 2013     sorafenib + paclitaxelpaclitaxel alone 1st line HER-2 negative Low risk of bias negative-21%2%

renal-cell carcinoma (advanced)

apitolisib
Powles, 2014   apitolisibeverolimus -
axitinib
AXIS (Rini), 2011      NCTaxitinibsorafenibsuggesting-34%
Qin, 2012   axitinibsorafenib -
cabozantinib
METEOR, 2015    NCTcabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line Risk of bias suggesting-42%-33%
CABOSUN, 2017      NCTcabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line Exploratory suggesting-34%
dovitinib
GOLD      NCTdovitinibsorafenibRisk of bias negative-14%
pazopanib
Sternberg, 2010     pazopanibplaceboLow risk of bias suggesting-54%
VEG105192, 2010        NCTpazopanibplacebosuggesting-54%-9%
COMPARZ, 2013      NCTpazopanibsunitinibnegative5%-9%
sorafenib
Escudier, 2009     sorafenibinterferon alphaExploratory negative-12%
TARGET, 2007          NCTsorafenibplaceboLow risk of bias suggesting-56%-12%
Ratain, 2006     sorafenibplaceboExploratory -
sunitinib
Motzer, 2007          NCTsunitinibinterferon alphasuggesting-58%-18%
SWITCH      NCTsunitinibsorafenib -
tivozanib
TIVO-1, 2013      NCTtivozanibsorafenibsuggesting-20%25%